BKM-120 (buparlisib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BKM-120 (buparlisib), covering 2017-01-06 to 2017-01-25. Get the full timeline:
Most recent: Clinical Trial Update: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer [Phase 1]